Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granule in Stage II/III NSCLC
NCT03198117Phase 4Terminated
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of huaier granule in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Qidong Gaitianli Medicines Co., Ltd. Primary endpoint: Disease-Free Survival at 2 years. Started Apr 2017; status: terminated.
02
Drugs
huaier granule
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03198117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198117.